Phuong N. Huynh

Array ( [id] => 6015004 [patent_doc_number] => 20020102260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-08-01 [patent_title] => 'Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue' [patent_app_type] => new [patent_app_number] => 09/956095 [patent_app_country] => US [patent_app_date] => 2001-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 17478 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0102/20020102260.pdf [firstpage_image] =>[orig_patent_app_number] => 09956095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5969014 [patent_doc_number] => 20020091082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-07-11 [patent_title] => 'Methods of modulating symptoms of hypertension' [patent_app_type] => new [patent_app_number] => 09/952350 [patent_app_country] => US [patent_app_date] => 2001-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23534 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0091/20020091082.pdf [firstpage_image] =>[orig_patent_app_number] => 09952350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6208951 [patent_doc_number] => 20020072066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-06-13 [patent_title] => 'Human osteoporosis gene' [patent_app_type] => new [patent_app_number] => 09/952360 [patent_app_country] => US [patent_app_date] => 2001-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22622 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0072/20020072066.pdf [firstpage_image] =>[orig_patent_app_number] => 09952360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5999874 [patent_doc_number] => 20020028495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-03-07 [patent_title] => 'Deoxyribonuclease II beta proteins and cDNAs' [patent_app_type] => new [patent_app_number] => 09/949434 [patent_app_country] => US [patent_app_date] => 2001-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2736 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0028/20020028495.pdf [firstpage_image] =>[orig_patent_app_number] => 09949434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6110420 [patent_doc_number] => 20020172673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-21 [patent_title] => 'Method for down-regulating IgE' [patent_app_type] => new [patent_app_number] => 09/949375 [patent_app_country] => US [patent_app_date] => 2001-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 21177 [patent_no_of_claims] => 69 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0172/20020172673.pdf [firstpage_image] =>[orig_patent_app_number] => 09949375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5985116 [patent_doc_number] => 20020098198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-07-25 [patent_title] => 'Oral drug delivery system' [patent_app_type] => new [patent_app_number] => 09/943691 [patent_app_country] => US [patent_app_date] => 2001-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4483 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20020098198.pdf [firstpage_image] =>[orig_patent_app_number] => 09943691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7460130 [patent_doc_number] => 20040052786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-03-18 [patent_title] => 'Erbb4 antagonists' [patent_app_type] => new [patent_app_number] => 10/362380 [patent_app_country] => US [patent_app_date] => 2003-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 29356 [patent_no_of_claims] => 84 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0052/20040052786.pdf [firstpage_image] =>[orig_patent_app_number] => 10362380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6159517 [patent_doc_number] => 20020147313 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-10 [patent_title] => 'Isolated bovine IgG heavy chain protein and its use as an antimicrobial' [patent_app_type] => new [patent_app_number] => 09/941965 [patent_app_country] => US [patent_app_date] => 2001-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3095 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0147/20020147313.pdf [firstpage_image] =>[orig_patent_app_number] => 09941965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1020842 [patent_doc_number] => 06887472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2005-05-03 [patent_title] => 'Anti-IgE vaccines' [patent_app_type] => utility [patent_app_number] => 09/938700 [patent_app_country] => US [patent_app_date] => 2001-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 30 [patent_no_of_words] => 18471 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/887/06887472.pdf [firstpage_image] =>[orig_patent_app_number] => 09938700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 906292 [patent_doc_number] => 07332168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2008-02-19 [patent_title] => 'Composition for the elimination of autoreactive B-cells' [patent_app_type] => utility [patent_app_number] => 10/362591 [patent_app_country] => US [patent_app_date] => 2001-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 26 [patent_no_of_words] => 20535 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/332/07332168.pdf [firstpage_image] =>[orig_patent_app_number] => 10362591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6276671 [patent_doc_number] => 20020106793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-08-08 [patent_title] => 'Tissue engineering scaffolds promoting matrix protein production' [patent_app_type] => new [patent_app_number] => 09/935168 [patent_app_country] => US [patent_app_date] => 2001-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 4867 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0106/20020106793.pdf [firstpage_image] =>[orig_patent_app_number] => 09935168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6590114 [patent_doc_number] => 20020041873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-04-11 [patent_title] => 'Methods and compositions for treating IgE-related disease using NNT-1 inhibitors' [patent_app_type] => new [patent_app_number] => 09/931704 [patent_app_country] => US [patent_app_date] => 2001-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10371 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0041/20020041873.pdf [firstpage_image] =>[orig_patent_app_number] => 09931704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6934430 [patent_doc_number] => 20010055774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-12-27 [patent_title] => 'Methods and compositions for the modulation of acid-sphingomyelinase-related apoptosis' [patent_app_type] => new [patent_app_number] => 09/928872 [patent_app_country] => US [patent_app_date] => 2001-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10601 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0055/20010055774.pdf [firstpage_image] =>[orig_patent_app_number] => 09928872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 679146 [patent_doc_number] => 07083788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-08-01 [patent_title] => 'Modulators of the function of receptors of the TNF/NGF receptor family and other proteins' [patent_app_type] => utility [patent_app_number] => 09/927458 [patent_app_country] => US [patent_app_date] => 2001-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20232 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/083/07083788.pdf [firstpage_image] =>[orig_patent_app_number] => 09927458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6016048 [patent_doc_number] => 20020102708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-08-01 [patent_title] => 'SH3-containing proteins' [patent_app_type] => new [patent_app_number] => 09/925122 [patent_app_country] => US [patent_app_date] => 2001-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20818 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0102/20020102708.pdf [firstpage_image] =>[orig_patent_app_number] => 09925122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1088808 [patent_doc_number] => 06828091 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-12-07 [patent_title] => 'Method of identifying immunosuppressive agents' [patent_app_type] => B2 [patent_app_number] => 09/920332 [patent_app_country] => US [patent_app_date] => 2001-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 11401 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/828/06828091.pdf [firstpage_image] =>[orig_patent_app_number] => 09920332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6156767 [patent_doc_number] => 20020146422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-10 [patent_title] => 'Compositions for inducing self-specific anti-IgE antibodies and uses thereof' [patent_app_type] => new [patent_app_number] => 09/916230 [patent_app_country] => US [patent_app_date] => 2001-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15739 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0146/20020146422.pdf [firstpage_image] =>[orig_patent_app_number] => 09916230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6080717 [patent_doc_number] => 20020081691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-06-27 [patent_title] => 'Delta 1-pyrroline-5-carboxylate reductase homolog' [patent_app_type] => new [patent_app_number] => 09/912717 [patent_app_country] => US [patent_app_date] => 2001-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 22259 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0081/20020081691.pdf [firstpage_image] =>[orig_patent_app_number] => 09912717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1395346 [patent_doc_number] => 06534050 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-03-18 [patent_title] => '2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes' [patent_app_type] => B1 [patent_app_number] => 09/889782 [patent_app_country] => US [patent_app_date] => 2001-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 4732 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/534/06534050.pdf [firstpage_image] =>[orig_patent_app_number] => 09889782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6715432 [patent_doc_number] => 20030026780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-06 [patent_title] => 'Innate immunity mediated methods of treating pathological conditions' [patent_app_type] => new [patent_app_number] => 09/910144 [patent_app_country] => US [patent_app_date] => 2001-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20252 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0026/20030026780.pdf [firstpage_image] =>[orig_patent_app_number] => 09910144 [rel_patent_id] =>[rel_patent_doc_number] =>)